<DOC>
	<DOCNO>NCT02036515</DOCNO>
	<brief_summary>This safety efficacy study ertugliflozin ( MK-8835/PF-04971729 ) treatment participant type 2 diabetes mellitus inadequate glycemic control metformin sitagliptin . The primary objective trial ass hemoglobin A1C ( A1C ) -lowering efficacy addition ertugliflozin compare addition placebo underlie hypothesis addition treatment ertugliflozin provide great reduction A1C compare addition placebo ; primary objective test 5-mg 15-mg dos ertugliflozin .</brief_summary>
	<brief_title>Safety Efficacy Ertugliflozin Treatment Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Metformin Sitagliptin ( MK-8835-006 )</brief_title>
	<detailed_description>The duration trial approximately 69 week . This include 1-week Screening Period , 12-week wash-off/titration /dose-stabilization period , 2-week single-blind , placebo run-in period , 52-week double-blind , placebo-controlled treatment period ( include 26-week Phase A 26-week Phase B ) , post-treatment telephone contact 14 day last dose blind investigational product .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Diagnosis type 2 diabetes mellitus ( T2DM ) On stable diabetes therapy metformin either sitagliptin another dipeptidyl peptidase4 ( DPP4 ) inhibitor sulfonylurea ( SU ) prior study participation willing washoff/switch another DPP4 inhibitor/SU sitagliptin Body Mass Index ( BMI ) great equal 18.0 kg/m^2 Male , postmenopausal female surgically sterile female If female reproductive potential , agree remain abstinent use ( partner use ) 2 acceptable combination birth control participate trial 14 day last use study drug History type 1 diabetes mellitus history ketoacidosis History specific type diabetes ( e.g. , genetic syndrome , secondary pancreatic diabetes , diabetes due endocrine disorder , drug chemicalinduced , postorgan transplant ) A know hypersensitivity intolerance sodiumglucose cotransporter 2 ( SGLT2 ) DPP4 inhibitor On weightloss program weightloss medication medication associate weight change weight stable Has undergone bariatric surgery within past 12 month &gt; 12 month weight stable Has treat insulin ( except shortterm use [ &lt; = 7 day ] ) , injectable antihyperglycemic agent ( AHAs ) ( e.g. , pramlintide , exenatide , liraglutide ) , pioglitazone rosiglitazone , sodiumglucose cotransporter 2 ( SGLT2 ) inhibitor , alpha glucosidase inhibitor meglitinides , bromocriptine ( Cycloset™ ) , colesevelam ( Welchol™ ) , nonapproved AHAs within 12 week study participation Has active , obstructive uropathy indwell urinary catheter History myocardial infarction , unstable angina , arterial revascularization , stroke , transient ischemic attack , New York Heart Association ( NYHA ) functional class IIIIV heart failure within 3 month study participation A history malignancy ≤5 year prior study participation , except adequately treat basal squamous cell skin cancer situ cervical cancer Known history Human Immunodeficiency Virus ( HIV ) Has blood dyscrasia disorder cause hemolysis unstable red blood cell clinically significant hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) A medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , active symptomatic gallbladder disease Has clinically significant malabsorption condition If take thyroid replacement therapy , stable dose least 6 week prior study participation Has previously randomize study ertugliflozin Has participate study involve investigational drug within 30 day prior study participation Has undergone surgical procedure within 6 week prior plan major surgery study participation Has positive urine pregnancy test Is pregnant breastfeeding , plan conceive trial , include 14 day follow last dose study medication Planning undergo hormonal therapy preparation donate egg trial , include 14 day follow last dose study medication Excessive consumption alcoholic beverage binge drinking Has donate blood blood product within 6 week study participation plan donate blood blood product time trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>